arrow
B

Brian Angus

Department of Clinical Infection
H指数:75
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV
AIDS
IF3.1
2024-06-251
OAAI
Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis

慢性乏力综合征和肌痛性脑脊髓炎的尼斯指南中审查过程中的异常和证据的解释

2023-07-1012
OA
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
LANCET
IF88.5
2021-09-01175
OAAI
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (vol 27, pg 270, 2021)
2021-05-215
OAAI
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (vol 27, pg 279, 2021)
2021-05-066
OAAI
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

ChAdOx1 nCoV-19 (AZD1222) 疫苗对SARS-CoV-2相关变异202012/01 (B.1.1.7) 的疗效: 一项随机对照试验的探索性分析

LANCET
IF88.5
2021-04-01410
OAAI
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
LANCET
IF88.5
2021-03-01841
OAAI
Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge
2021-01-01412
OAAI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

ChAdOx1 nCoV-19疫苗 (AZD1222) 抗SARS-CoV-2的安全性和有效性: 对巴西、南非和英国的四项随机对照试验的中期分析

LANCET
IF88.5
2021-01-013.2K
OAAI
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
2020-12-17454
OAAI
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
2020-12-17233
OAAI
Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model
2020-10-2021
OAAI
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

ChAdOx1 nCoV-19疫苗抗SARS-CoV-2的安全性和免疫原性: 1/2期单盲随机对照试验的初步报告

LANCET
IF88.5
2020-08-011.7K
OAAI
Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model
2019-07-0332
OAAI
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
2019-05-0136
OAAI